by Medindia Content Team on  July 3, 2006 at 9:21 AM Drug News
Dr Reddys Launches New Drug In Its Urology Segment
Consolidating its position in the urology segment, pharma major Dr Reddys Laboratories Ltd has introduced a drug Alfuzosin Hydrochloride available in extended release tablets of 10 mg dosage.

Alfuzosin Hydrochloride, introduced under the brand name 'Alfoo' is indicated for treatment of enlargement of prostate gland in ageing men known as Benign Prostatic Hyperplasia (BPH), a company release said.

The product was launched nationwide, and would further help the company consolidate its position in the urology segment which has over 10 products in the urology segment, the company informed the Bombay Stock Exchange.

The product is now available in over 5,700 retail counters across the nation and marketed by over 100 scientific business officers, it added.

The market size for the product as per April 2006 market data is valued at Rs 27 crore and the urology segment is estimated at Rs 65.08 crore.

Alfuzosin provides rapid relief from signs and symptoms of Benign Prostatic Hyperplasia (BPH) is a most common disorder among ageing men. The prevalence of BPH increases from 8 per cent in men between 31 and 40 years of age to 50 per cent in men between 51 and 60 years of age.

The shares of the company were trading at Rs 1,274.95, 0.07 per cent at the BSE

Source:PTI News

Most Popular on Medindia